These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 23449496)

  • 1. The economics of active surveillance for prostate cancer.
    Dall'Era MA
    Curr Opin Urol; 2013 May; 23(3):278-82. PubMed ID: 23449496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic analysis of active surveillance for localized prostate cancer.
    Kim S; Dall'Era MA; Evans CP
    Curr Opin Urol; 2012 May; 22(3):247-53. PubMed ID: 22388666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the healthcare costs of treating prostate cancer in Australia: A Markov modelling analysis.
    Gordon LG; Tuffaha HW; James R; Keller AT; Lowe A; Scuffham PA; Gardiner RA
    Urol Oncol; 2018 Mar; 36(3):91.e7-91.e15. PubMed ID: 29169847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active surveillance for prostate cancer compared with immediate treatment: an economic analysis.
    Keegan KA; Dall'Era MA; Durbin-Johnson B; Evans CP
    Cancer; 2012 Jul; 118(14):3512-8. PubMed ID: 22180322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
    Laviana AA; Ilg AM; Veruttipong D; Tan HJ; Burke MA; Niedzwiecki DR; Kupelian PA; King CR; Steinberg ML; Kundavaram CR; Kamrava M; Kaplan AL; Moriarity AK; Hsu W; Margolis DJ; Hu JC; Saigal CS
    Cancer; 2016 Feb; 122(3):447-55. PubMed ID: 26524087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Economic features of active surveillance].
    Huguet J; Musquera M; Ribal MJ; Alcaraz A
    Arch Esp Urol; 2014 Jun; 67(5):509-13. PubMed ID: 24914850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
    Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
    Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active surveillance: the Canadian experience.
    Klotz L
    Curr Opin Urol; 2012 May; 22(3):222-30. PubMed ID: 22453335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI and surveillance.
    Ouzzane A; Puech P; Villers A
    Curr Opin Urol; 2012 May; 22(3):231-6. PubMed ID: 22388665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer.
    Aizer AA; Paly JJ; Zietman AL; Nguyen PL; Beard CJ; Rao SK; Kaplan ID; Niemierko A; Hirsch MS; Wu CL; Olumi AF; Michaelson MD; D'Amico AV; Efstathiou JA
    J Clin Oncol; 2012 Sep; 30(25):3071-6. PubMed ID: 22851571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prostate cancer Research International: Active Surveillance study.
    Bangma CH; Bul M; Roobol M
    Curr Opin Urol; 2012 May; 22(3):216-21. PubMed ID: 22453333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
    Loeb S; Berglund A; Stattin P
    J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.
    Hayes JH; Ollendorf DA; Pearson SD; Barry MJ; Kantoff PW; Lee PA; McMahon PM
    Ann Intern Med; 2013 Jun; 158(12):853-60. PubMed ID: 23778902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active surveillance: oncologic outcome.
    Venderbos LD; Bokhorst LP; Bangma CH; Roobol MJ
    Curr Opin Urol; 2013 May; 23(3):268-72. PubMed ID: 23425994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
    Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
    Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
    JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
    Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
    BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost comparison between watchful waiting with active surveillance and active treatment of clinically localized prostate cancer.
    Corcoran AT; Peele PB; Benoit RM
    Urology; 2010 Sep; 76(3):703-7. PubMed ID: 20381846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A decision analysis comparing 3 active surveillance protocols for the treatment of patients with low-risk prostate cancer.
    White C; Nimeh T; Gazelle GS; Weinstein MC; Loughlin KR
    Cancer; 2019 Mar; 125(6):952-962. PubMed ID: 30561761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.